Recombinant SARS-CoV-2 RBD (HEK)

The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor. The SARS-CoV-2 RBD (HEK) protein covers amino acids R319 to S591 of the spik

... read more
Choose your product:

Related products for Recombinant SARS-CoV-2 RBD (HEK)

Product data and images for Recombinant SARS-CoV-2 RBD (HEK)
Figure 1

Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 2

Cell-based RBD binding assay. Schematic overview illustrating how our biotinylated RBD can be applied to analyze binding to ACE2-expressing cells. Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 3

Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 RBD (HEK). The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.

Figure 4

Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 RBD (HEK). ACE2-expressing cells were incubated with different concentrations of biotinylated Recombinant SARS-CoV-2 RBD (HEK). ACE2-bound RBD was subsequently detected by fluorescent staining and the amount of positive cells is shown.

Figure 5

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 RBD (HEK) under reduced (R) and non-reduced (NR) conditions.

Figure 6

Mass spectrometry analysis (ESI-MS) of Recombinant SARS-CoV-2 RBD (HEK). The non-biotinylated protein was analyzed and the peak corresponds to the deglycosylated molecular mass (33839 Da).

Figure 7

Size-exclusion chromatography (SEC) of Recombinant SARS-CoV-2 RBD (HEK). The non-biotinylated protein was analyzed and the peak corresponds to the monomeric protein.

Specifications for Recombinant SARS-CoV-2 RBD (HEK)
Overview

The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor. The SARS-CoV-2 RBD (HEK) protein covers amino acids R319 to S591 of the spike protein and contains a His-tag and an AviTag™. Recombinant SARS-CoV-2 RBD (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the RBD.

Resources for Recombinant SARS-CoV-2 RBD (HEK)
Citations for Recombinant SARS-CoV-2 RBD (HEK)
Publications
  1. Hsieh, S-M. et al. (2021) Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine 38 (doi: 10.1016/j.eclinm.2021.100989)

You have previously chosen International as your location.
What do you want to do?